

Total Knee Joint Replacement in Hemophilia Patient: A Comprehensive Review

Ahmed.I.Al-Salali, Hosam.A.Al-bigawy and Elsayed.M.Bayoumy

Orthopedic Surgery Dept., Faculty of Medicine, Benha University

E-mail: ahmadalsalali98@gmail.com

Abstract

Background: Hemophilia is a bleeding illness characterised by insufficient clotting factors, which may cause significant knee joint injury. Total Knee Joint Replacement (TKJR) has proposed as a promising therapy choice for Hemophilia patients with significant knee joint degeneration, with the goals of restoring joint function and reducing discomfort. **Objectives:** This study investigates the importance of TKJR in Hemophilia patients, focusing on preoperative concerns, surgical techniques, postoperative treatment, results, and problems exclusive to this community. **Conclusions:** TKJR has shown to be an effective therapeutic choice for people with significant knee joint degeneration due to haemophilia. Through a multidisciplinary approach, involving hematologists, orthopedic surgeons, and anesthesiologists, along with personalized care and thorough preoperative evaluation, successful outcomes can be achieved. Intraoperative clotting factor replacement therapy plays a crucial role in maintaining hemostasis during surgery. Postoperative management, including pain management, wound healing, and rehabilitation, contributes to functional recovery and improved quality of life. Although Hemophilia-specific complications exist, ongoing research, advancements in surgical techniques, implant materials, and gene therapy hold promise for further enhancing outcomes. Patient education, self-care, and adherence to prophylactic treatment are paramount in achieving long-term success. Continued collaboration and research efforts are necessary to optimize outcomes and improve the lives of Hemophilia patients undergoing TKJR.

Keywords: Total Knee Joint Replacement; Hemophilia; Surgical Procedure.

1. Introduction

Hemophilia is a rare genetic bleeding disorder characterized by deficient or malfunctioning clotting factors, leading to prolonged and spontaneous bleeding. It predominantly affects males, with Hemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) being the most common types. While Hemophilia primarily manifests as spontaneous bleeding into muscles and joints, the impact on joint health, particularly the knee joints, is of significant concern [1].

The repeated episodes of bleeding in Hemophilia can result in chronic synovitis (inflammation of the synovial membrane), hemophilic arthropathy, and progressive joint destruction. The knee joint, being one of the largest weight-bearing joints, is particularly susceptible to damage. Hemophilia-related knee joint complications include chronic pain, swelling, limited range of motion, muscle weakness, and ultimately, severe joint dysfunction [2].

In cases where conservative management approaches, such as physical therapy, pain management, and prophylactic clotting factor replacement therapy, fail to alleviate symptoms and preserve joint function, Total Knee Joint Replacement (TKJR) emerges as a valuable treatment option. TKJR involves the surgical replacement of the damaged knee joint components with artificial prostheses, aiming to alleviate pain, restore mobility, and improve overall quality of life [3].

The significance of TKJR in Hemophilia patients with severe joint damage cannot be overstated. By replacing the damaged knee joint

with an artificial implant, TKJR offers the potential for pain relief, improved joint stability, enhanced functionality, and increased mobility. It can significantly restore the ability to perform daily activities, participate in physical exercises, and improve overall functional outcomes in Hemophilia patients who have experienced extensive joint deterioration [4].

While TKJR has promise for Hemophilia patients, it is important to consider a number of aspects, including as the patient's clotting factor levels, joint state, general health, and the necessity for rigorous preoperative preparation and postoperative treatment. Additionally, potential complications related to bleeding, infection, or implant-related issues should be carefully evaluated and managed to ensure optimal outcomes [5].

TKJR represents a crucial treatment option for Hemophilia patients who have sustained severe knee joint damage. By addressing the debilitating effects of Hemophilia-related arthropathy, TKJR can offer improved quality of life and functional outcomes for these individuals. However, a multidisciplinary approach involving hematologists, orthopedic surgeons, and anesthesiologists, along with meticulous preoperative and postoperative management, is essential to ensure the safety and success of the procedure [6].

The objective of this review is to comprehensively analyze and evaluate the utilization of TKJR as a treatment option in Hemophilia patients with severe knee joint damage, considering the impact of Hemophilia on

joint health, discussing the surgical procedure, preoperative considerations, postoperative management, outcomes, complications, and future perspectives [7].

2. Preoperative Considerations

Achieving successful outcomes in TKJR for Hemophilia patients requires careful preoperative planning and coordination among a multidisciplinary team comprising hematologists, orthopedic surgeons, and anesthesiologists. This collaborative approach is vital to ensure optimal patient care and minimize the risks associated with the surgery [8].

Thorough preoperative evaluation is crucial before proceeding with TKJR in Hemophilia patients. This evaluation should encompass assessing the patient's clotting factor levels to determine the severity of their Hemophilia and guide appropriate management strategies. Evaluating joint status through imaging techniques such as X-rays or magnetic resonance imaging (MRI) helps gauge the extent of knee joint damage and plan the surgical approach accordingly [9].

Assessing the patient's overall health is equally important in the preoperative phase. Hemophilia patients may have comorbidities or underlying medical conditions that need to be addressed and optimized before surgery. This assessment helps determine the patient's fitness for anesthesia and surgery and ensures adequate preparation for a successful TKJR [10].

Prophylactic clotting factor replacement therapy plays a critical role in minimizing the risk of bleeding during and after TKJR. By administering clotting factor concentrates before and after surgery, the patient's clotting factor levels can be temporarily raised to normal or near-normal levels, reducing the chances of excessive bleeding during the procedure and facilitating proper wound healing postoperatively. The specific dosing regimen and timing of clotting factor replacement therapy may vary based on individual patient characteristics and surgeon preferences [11].

A multidisciplinary approach involving hematologists, orthopedic surgeons, and anesthesiologists is essential in the preoperative phase of TKJR for Hemophilia patients. Thorough **Hemophilia-specific considerations may include:**

✓ **Preoperative clotting factor replacement therapy:**

Hemophilia patients may receive clotting factor concentrates before surgery to temporarily raise their clotting factor levels, minimizing the risk of excessive bleeding during the procedure [19].

✓ **Hemostatic measures:**

Special attention is given to meticulous hemostasis during surgery, including the use of electrocautery, surgical sealants, or hemostatic

evaluation of clotting factor levels, joint status, and overall health guides treatment decisions and helps optimize patient outcomes. Additionally, the implementation of prophylactic clotting factor replacement therapy significantly contributes to minimizing bleeding risks and promoting successful surgical outcomes [12].

3. Surgical Procedure

Total Knee Joint Replacement (TKJR) is a surgical procedure that involves replacing the damaged knee joint components with artificial prostheses to restore joint function and alleviate pain. The following is an overview of the key steps involved in TKJR [13]:

a) Incision and Exposure:

A surgical incision is made over the knee joint, allowing access to the damaged joint structures. The surgeon carefully exposes the knee joint, protecting nearby blood vessels and nerves [14].

b) Resection of Damaged Tissues:

The damaged cartilage, bone, and other affected tissues within the knee joint are removed. This includes the resection of the femoral condyles, tibial plateau, and sometimes the patella (kneecap) [15].

c) Implant Placement:

Artificial prosthetic components are then secured to the resected bone surfaces. These components typically consist of metal alloys (such as cobalt-chromium or titanium) and high-density polyethylene. The femoral, tibial, and patellar components are fixed in place with bone cement or press-fit techniques, depending on the specific case [16].

d) Ligament Balancing:

The surgeon carefully balances the tension in the surrounding ligaments to optimize joint stability and ensure proper alignment of the artificial components [17].

e) Closure:

Once the prosthetic components are in place, the incision is closed with sutures or staples, and dressings are applied to protect the wound [18].

In Hemophilia patients undergoing TKJR, modifications or adaptations may be necessary to minimize the risk of bleeding and optimize surgical outcomes [18]. agents, to control bleeding and maintain hemostasis [20].

✓ **Surgical technique:**

Surgeons may employ meticulous surgical techniques to minimize tissue trauma and bleeding. This may involve using smaller incisions, employing precise soft tissue handling, and carefully controlling bone cuts [21].

✓ **Implant materials:**

The choice of implant materials may be influenced by the patient's Hemophilia type and severity. Implants with surfaces that promote

osseointegration and minimize wear and friction, such as highly cross-linked polyethylene, may be preferred [22].

Intraoperative clotting factor delivery is of the utmost significance for TKJR patients with haemophilia. Continuous administration of clotting factor concentrates during surgery helps maintain hemostasis, control bleeding, and minimize the risk of postoperative complications [22].

4. Postoperative Management

The postoperative care of Hemophilia patients after TKJR is crucial for achieving optimum recovery, pain control, wound healing, and joint function restoration [23].

The following concerns are crucial in the postoperative management of these patients:

Post-Operative Care objectives:

The major objectives of postoperative care are pain relief, wound repair, preventing complications, and optimising functional results. To maximise patient comfort and promote early mobility, pain control methods, involving analgesic drugs usage and non-pharmacological methods like cold treatment and elevation, are adopted [24].

Continuous Clotting Factor Replacement:

In the immediate postoperative period, continuous clotting factor replacement therapy is crucial to maintain hemostasis and prevent bleeding complications. By ensuring adequate clotting factor levels, the risk of excessive bleeding at the surgical site and in the surrounding tissues is minimized. The specific dosing regimen and duration of clotting factor replacement are tailored to each patient based on their Hemophilia type, severity, and individual response [25].

Physiotherapy and Rehabilitation:

Rehabilitation and Physiotherapy are essential for the restoration and recovery of joint function after TKJR. Hemophilia patients receiving TKJR benefit from rehabilitation regimens that emphasise developing surrounding muscles, boosting joint motion range, and promoting general mobility. Physiotherapists instruct patients in particular exercises and movement patterns that help in recovering knee joint stability, functional strength, and flexibility [26].

Gradual Progression of Activities:

Postoperative management also involves a gradual progression of activities and weight-bearing as tolerated. Patients are initially mobilized with the help of assistive devices such as crutches or walkers, gradually transitioning to partial and then full weight-bearing. Close monitoring by the healthcare team ensures that the patient's progress is appropriate, and any concerns or complications are promptly addressed [27].

Follow-up and Monitoring:

Regular follow-up appointments are essential to monitor the patient's progress, evaluate wound

healing, and assess the functionality of the TKJR. Hemophilia patients may require closer monitoring due to their inherent bleeding risks, and ongoing communication between the hematologist, orthopedic surgeon, and physiotherapist is important to optimize care [28].

Finally, postoperative management after TKJR in Hemophilia patients aims to address pain, promote wound healing, prevent complications, and facilitate functional recovery. Continuous clotting factor replacement therapy ensures hemostasis during the immediate postoperative period. Physiotherapy and rehabilitation exercises are integral in restoring joint function, improving mobility, and enhancing the overall quality of life for Hemophilia patients undergoing TKJR [29].

5. Outcomes and Complications:

Total Knee Joint Replacement (TKJR) in Hemophilia patients has shown promising results in terms of improving functional outcomes and quality of life. While individual patient experiences may vary, data suggests favorable success rates in this specific population [7].

Studies have reported significant improvements in pain relief, joint stability, range of motion, and functional abilities following TKJR in Hemophilia patients. The reduction in pain allows patients to engage in daily activities, participate in physical exercises, and enhance their overall quality of life. Improved joint stability and mobility contribute to increased independence and functional capacity [30, 31].

However, it is essential to recognise and manage the possibility of problems in Hemophilia patients having TKJR. Among these consequences involve bleeding, infection, and implant-related problems. Due to the intrinsic lack of coagulation factors, Hemophilia patients have an elevated risk of bleeding throughout and following surgical procedures. Intensive monitoring of clotting factor levels and rigorous hemostasis methods are essential for mitigating this risk throughout the surgery. Prophylactic clotting factor replacement therapy plays a significant role in mitigating bleeding complications [32].

Infection is another potential complication that requires careful consideration in Hemophilia patients. Proper sterile techniques during surgery, appropriate antibiotic prophylaxis, and close monitoring for signs of infection are essential. Prompt diagnosis and intervention are crucial in managing infections to prevent implant failure or systemic spread [33].

Implant-related issues, such as implant loosening, wear, or dislocation, can occur over the long term. Hemophilia patients may have unique challenges related to implant durability due to their higher risk of bleeding, reduced bone quality, or altered joint mechanics. Regular follow-up and

monitoring are necessary to detect and address these issues in a timely manner. Close collaboration between hematologists and orthopedic surgeons is vital to ensure optimal long-term outcomes [34].

Long-term durability of knee implants in Hemophilia patients is an ongoing area of research. With advancements in implant materials and surgical techniques, efforts are being made to improve implant longevity and reduce complications specific to this patient population. Long-term follow-up studies are crucial to evaluate the success and longevity of knee implants in Hemophilia patients [5].

6. Future Perspectives

The field of TKJR in Hemophilia patients continues to evolve, with ongoing research and advancements aimed at improving outcomes and reducing complications. Several emerging techniques and considerations are being explored to tailor TKJR specifically for Hemophilia patients [4].

Personalized Surgical Approaches: Efforts are being made to develop personalized surgical approaches based on the patient's Hemophilia type, severity, and joint condition. Individualized treatment plans may involve modifications in surgical techniques, implant selection, and postoperative management to optimize outcomes [35].

Minimally Invasive Surgery: Minimally invasive surgical techniques, such as arthroscopy-assisted or computer-assisted TKJR, are being explored for Hemophilia patients. These approaches aim to reduce surgical trauma, enhance joint visualization, and potentially lead to faster recovery and improved functional outcomes [36].

Implant Materials and Design: Advancements in implant materials and design are focused on improving implant longevity and reducing wear-related complications. Enhanced surface coatings, highly cross-linked polyethylene, and improved fixation techniques are being investigated to address the unique challenges of Hemophilia patients, such as their higher risk of bleeding and altered joint mechanics [37].

Gene Therapy: Gene therapy is an emerging field that holds promise for Hemophilia patients. Ongoing research aims to develop innovative approaches to deliver clotting factor genes to restore or enhance clotting factor production in Hemophilia patients. Successful gene therapy could potentially eliminate or reduce the need for prophylactic treatment and improve long-term outcomes in TKJR [38].

Patient Education and Self-Care: Patient education plays a crucial role in optimizing long-term results. Empowering Hemophilia patients with knowledge about their condition, emphasizing

the importance of self-care, and promoting adherence to prophylactic treatment can help minimize bleeding risks, reduce complications, and enhance functional outcomes following TKJR [39].

Clinical Trials and Research: Ongoing clinical trials and research studies are focused on evaluating the effectiveness of different treatment strategies, surgical techniques, implant materials, and postoperative management approaches in Hemophilia patients undergoing TKJR. These studies aim to generate robust evidence and refine treatment protocols to further enhance patient outcomes [40].

The future of TKJR in Hemophilia patients holds promising prospects with emerging techniques and advancements specifically tailored to address the unique challenges of this population. Personalized surgical approaches, minimally invasive techniques, improvements in implant materials and design, gene therapy, patient education, and ongoing research efforts are all contributing to the optimization of outcomes and reduction of complications. Continued collaboration between healthcare professionals, patient engagement, and adherence to prophylactic treatment are essential in achieving optimal long-term results in TKJR for Hemophilia patients [41].

7. Conclusion

TKJR is a viable and effective treatment option for Hemophilia patients with severe knee joint damage. With personalized care, multidisciplinary collaboration, and continued research, the outcomes and quality of life for Hemophilia patients undergoing TKJR can be further enhanced. By integrating advancements in surgical techniques, implant materials, and patient management, healthcare professionals can optimize the outcomes and improve the lives of Hemophilia patients seeking relief from severe knee joint damage through TKJR.

References

- [1] P.Mehta, A.K.R.Reddivari.Hemophilia. 2019
- [2] R. Gualtierotti, L.P. Solimeno, F. Peyvandi. Hemophilic arthropathy: Current knowledge and future perspectives. *J Thromb Haemost*;19:2112-21. 2021
- [3] D.U. Jette, S.J. Hunter, L. Burkett, B. Langham, D.S. Logerstedt, N.S. Piuze, et al. Physical Therapist Management of Total Knee Arthroplasty. *Phys Ther*;100:1603-31. 2020
- [4] S.J. Mortazavi, N. Bagheri, A. Farhoud, S. Hadi Kalantar, E. Ghadimi. Total Knee Arthroplasty in Patients with Hemophilia: What Do We Know? *Arch Bone Jt Surg*;8:470-8. 2020
- [5] N. Pathak, A.M. Munger, A. Charifa, W.B. Laskin, E. Bisson, G.M. Kupfer, et al.

- Total knee arthroplasty in hemophilia A. *Arthroplast Today*;6:52-8.e1. 2020
- [6] S. Lobet, C. Hermans, C. Lambert. Optimal management of hemophilic arthropathy and hematomas. *J Blood Med*;5:207-18. 2014
- [7] J.K. Bae, K.I. Kim, S.H. Lee, M.C. Yoo. Mid-to Long-Term Survival of Total Knee Arthroplasty in Hemophilic Arthropathy. *J Clin Med*;9. 2020
- [8] C.C. Wyles, H.M. Smith, A.W. Amundson, C.M. Duncan, A.D. Niesen, L.A. Ingalls, et al. Orthopedic Surgery and Anesthesiology Surgical Improvement Strategies Project: Phase I Outcomes. *J Arthroplasty*;36:823-9. 2021
- [9] A. Seuser, C. Djambas Khayat, C. Negrier, A. Sabbour, L. Heijnen. Evaluation of early musculoskeletal disease in patients with haemophilia: results from an expert consensus. *Blood Coagul Fibrinolysis*;29:509-20. 2018
- [10] D. Bhoi, L. Kashyap. Perioperative management of a patient with hemophilia A and crigler-najjar syndrome. *J Anaesthesiol Clin Pharmacol*;29:582-4. 2013
- [11] A. Iorio, C. Königs, M.T. Reding, D. Rotellini, M.W. Skinner, M.E. Mancuso, et al. Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature. *Haemophilia*;29:33-44. 2023
- [12] Y. Li, X.S. Weng, J. Lin, J. Jin, W.W. Qian, B.Z. Zhang, et al. Perioperative Period of a Hemophilia-related Osteoarthopathy Therapeutic Regimen and Analysis of Complications. *Orthop Surg*;8:60-7. 2016
- [13] X. Chen, Z. Wang, Y. Huang, W. Deng, Y. Zhou, M. Chu. Identification of novel biomarkers for arthrofibrosis after total knee arthroplasty in animal models and clinical patients. *EBioMedicine*;70:103486. 2021
- [14] R.B. R, S. Ramkumar, H. Venkatramani. Soft Tissue Coverage for Defects around the Knee Joint. *Indian J Plast Surg*;52:125-33. 2019
- [15] K. Rönn, N. Reischl, E. Gautier, M. Jacobi. Current surgical treatment of knee osteoarthritis. *Arthritis*;2011:454873. 2011
- [16] J. Pajarinen, T.H. Lin, T. Sato, Z. Yao, S.B. Goodman. Interaction of Materials and Biology in Total Joint Replacement - Successes, Challenges and Future Directions. *J Mater Chem B*;2:7094-108. 2014
- [17] P. Salari, A. Baldini. Revision knee surgery: the practical approach. *EFORT Open Rev*;6:495-500. 2021
- [18] R. Kulkarni. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects. *Haemophilia*;19:2-10. 2013
- [19] T. Mistry, N. Dogra, K. Chauhan, J. Shahani. Perioperative Considerations in a Patient with Hemophilia A: A Case Report and Review of Literature. *Anesth Essays Res*;11:243-5. 2017
- [20] A.M. Behrens, M.J. Sikorski, P. Kofinas. Hemostatic strategies for traumatic and surgical bleeding. *J Biomed Mater Res A*;102:4182-94. 2014
- [21] V. Bhattacharya. Management of soft tissue wounds of the face. *Indian J Plast Surg*;45:436-43. 2012
- [22] J.N. Poston, R. Kruse-Jarres. Perioperative hemostasis for patients with hemophilia. *Hematology Am Soc Hematol Educ Program*;2022:586-93. 2022
- [23] Y. Wu, H. Xue, W. Zhang, Y. Wu, Y. Yang, H. Ji. Application of enhanced recovery after surgery in total knee arthroplasty in patients with haemophilia A: A pilot study. *Nurs Open*;8:80-6. 2021
- [24] V. Garimella, C. Cellini. Postoperative pain control. *Clin Colon Rectal Surg*;26:191-6. 2013
- [25] R.F. Sidonio, Jr., M. Hoffman, G. Kenet, Y. Dargaud. Thrombin generation and implications for hemophilia therapies: A narrative review. *Res Pract Thromb Haemost*;7:100018. 2023
- [26] S. Lobet, E. Pendeville, R. Dalzell, A. Defalque, C. Lambert, D. Pothen, et al. The role of physiotherapy after total knee arthroplasty in patients with haemophilia. *Haemophilia*;14:989-98. 2008
- [27] J.T. Cavanaugh, M. Powers. ACL Rehabilitation Progression: Where Are We Now? *Curr Rev Musculoskelet Med*;10:289-96. 2017
- [28] W. Matrane, A. Nsiri, M. Rafai, F. Midmani, N. Boughaza, S. Cherkaoui, et al. A challenging management of hemophilia B patient with inhibitors undergoing major orthopedic surgeries in a resource-constrained country. *Clin Case Rep*;8:2995-9. 2020
- [29] T. Tateiwa, Y. Takahashi, T. Ishida, K. Kubo, T. Masaoka, T. Shishido, et al. Perioperative management of hemophilia patients receiving total hip and knee arthroplasty: a complication report of two cases. *Ther Clin Risk Manag*;11:1383-9. 2015
- [30] L.J. Geneen, R.A. Moore, C. Clarke, D. Martin, L.A. Colvin, B.H. Smith. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. *Cochrane Database Syst Rev*;4:Cd011279. 2017
- [31] J.K. Cooney, R.J. Law, V. Matschke, A.B. Lemmey, J.P. Moore, Y. Ahmad, et al. Benefits of exercise in rheumatoid arthritis. *J Aging Res*;2011:681640. 2011

- [32] S.P. Shastri, R. Kaul, K. Baroudi, D. Umar. Hemophilia A: Dental considerations and management. *J Int Soc Prev Community Dent*;4:S147-52. 2014
- [33] M.J.ENZLER, E. Berbari, D.R. Osmon. Antimicrobial prophylaxis in adults. *Mayo Clin Proc*;86:686-701. 2011
- [34] T. Wirth. The orthopaedic management of long bone deformities in genetically and acquired generalized bone weakening conditions. *J Child Orthop*;13:12-21. 2019
- [35] W. Stromer, I. Pabinger, C. Ay, R. Crevenna, J. Donnerer, C. Feistritzer, et al. Pain management in hemophilia: expert recommendations. *Wien Klin Wochenschr*;133:1042-56. 2021
- [36] L.F.D. van Vulpen, S. Thomas, S.A. Keny, S.S. Mohanty. Synovitis and synovectomy in haemophilia. *Haemophilia*;27 Suppl 3:96-102. 2021
- [37] K.K. Amirtharaj Mosas, A.R. Chandrasekar, A. Dasan, A. Pakseresht, D. Galusek. Recent Advancements in Materials and Coatings for Biomedical Implants. *Gels*;8. 2022
- [38] A.C. Nathwani. Gene therapy for hemophilia. *Hematology Am Soc Hematol Educ Program*;2019:1-8. 2019
- [39] L.H. Schrijvers, M.J. Schuurmans, K. Fischer. Promoting self-management and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals. *Haemophilia*;22:499-506. 2016
- [40] C. Bacci, A. Cerrato, G. Zanette, S. Pasca, E. Zanon. Regenerative Surgery with Dental Implant Rehabilitation in a Haemophiliac Patient. *TH Open*;5:e104-e6. 2021
- [41] F. Nossair, C.D. Thornburg. The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries. *Ther Adv Hematol*;9:239-49. 2018